Macrophages play important and diverse roles during cancer progression. However, cancer therapies based on macrophage modulation are lacking in tools that can recognize and deliver therapeutic payloads to macrophages in a tumor-specific manner. As a result, treatments tend to interfere with normal macrophage functions in healthy organs. We previously identified a macrophage-binding peptide, termed CRV. Here, we show that upon systemic administration into tumor-bearing mice, CRV selectively homes to tumors, extravasates, and preferentially binds to macrophages within. CRV exhibits a higher affinity for tumor macrophages than for other cells in tumors or for other macrophage types elsewhere in the body. We further identified and validated retinoid X receptor beta (RXRB) as the CRV receptor. Intriguingly, although it is known as a nuclear receptor, RXRB shows a prominent cell surface localization that is largely restricted to tumor macrophages. Systemic administration of anti-RXRB antibodies also results in tumor-selective binding to macrophages similar to CRV. Lastly, we demonstrate the ability of CRV to improve the delivery of nano-carriers into solid tumors and macrophages within. In summary, we describe here a novel cell surface marker and targeting tools for tumor macrophages that may aid in future development of macrophage-modulatory cancer therapies.
|Original language||English (US)|
|Number of pages||12|
|Journal||Journal of Controlled Release|
|State||Published - May 10 2019|
Bibliographical noteFunding Information:
This work was supported by grants from the National Cancer Institute ( R01CA214550 and R01CA188883 ) and the National Institutes of Biomedical Imaging and Bioengineering ( R21EB022652 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
© 2019 Elsevier B.V.
- Cargo delivery
- RXR beta targeting
- Tumor homing
- Tumor-associated macrophages